NEW ASPECTS OF THE PATHOPHYSIOLOGY OF CHRONIC URTICARIA



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic urticaria (CU) is characterized by a marked impact on quality of life, a considerable prevalence and an economic burden of direct and indirect healthcare costs. Despite advances in understanding of the pathophysiology of the disease, patients with CU mainly receive empiric treatment and there is no monitoring of the underlying inflammation in CU. The main aspects in the research into the pathophysiology of CU include genetic mechanisms, the role of functional autoantibodies, the characteristics of target cells and effector cells in the inflammation in CU, the regulation of the inflammation and the role of various mediators, acute phase proteins and hormones in the pathophysiology of CU. Research into the pathophysiological pathways of CU may lead to the definition of pathophysiological phenotypes of CU, the development of biomarkers of the underlying inflammation in CU and pathogenesis-based therapy for certain groups of CU patients.

Full Text

Restricted Access

About the authors

E Yu Borzova

Russian Medical Academy of Postgraduate Education

Email: eborzova@gmail.com
Department of Clinical Allergology Moscow

References

  1. Gaig P, Olona M., Munoz L.D. et al. Epidemiology of urticaria in Spain. J. Investig. Allergol. Clin. Immunol. 2004, v. 14 (3), p. 214-220.
  2. Khakoo G., Sofianou-Katsoulis A., Perkin M.R., Lack G. Clinical features and natural history of physical urticaria in children. Pediatr. Allergy Immunol. 2008, v. 19 (4), p. 363-366.
  3. O’Donnell B.F., Lawlor F., Simpson J. et al. The impact of chronic urticaria on the quality of life. Br. J. Dermatol. 1997, v. 136, (2), p. 197-201.
  4. Delong L.K., Culler S.D., Saini S.S. et al. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch. Dermatol. 2008, v. 144 (1), p. 35-39.
  5. Asero R. Chronic idiopathic urticaria: a family study. Ann. Allergy. Asthma Immunol. 2002, v. 89 (2), p. 195-196.
  6. Pan K.Y, Walls R.S., Rajasekariah P et al. Polymorphism of IgE gene in chronic urticaria. Immunol. Cell. Biol. 1996, v. 74 (1), p. 90-95.
  7. Bozek A., Krajewska J., Filipowska B. et al. HLA status in patients with chronic spontaneous urticaria. Int. Arch. Allergy Immunol. 2010, v. 153 (4), p. 419-423.
  8. Di Lorenzo G., Pacor M.L., Candore G. et al. Polymorphisms of cyclo-oxygenases and 5-lipo-oxygenase-activating protein are associated with chronic spontaneous urticaria and urinary leukotriene E4. Eur. J. Dermatol. 2011, v. 21 (1), p. 47-52.
  9. Akcali C., Ozkur M., Erbagci Z. et al. Association ofinsertion/ deletion polymorphism of the angiotensin-converting enzyme gene with angio-oedema accompanying chronic urticaria but not chronic urticaria without angio-oedema or the autologous serum skin test response. J. Eur. Acad. Dermatol. Venereol. 2008, v. 22 (1), p. 83-86.
  10. Brzoza Z., Grzeszczak W., Rogala B. et al. PTPN22 Polymorphism Presumably Plays a Role in the Genetic Background of Chronic Spontaneous Autoreactive Urticaria. Dermatology. 2012, v. 224 (4), p. 340-345.
  11. O’Donnell B.F., O’Neill C.M., Francis D.M. et al. Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br. J. Dermatol. 1999, v. 140 (5), p. 853-858.
  12. Bae J.S., Kim S.H., Ye YM. et al. Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. J. Allergy Clin. Immunol. 2007, v. 119 (2), p. 449-456.
  13. Park H.J., Ye YM., Hur G.Y. et al. Association between a TGFbeta1 promoter polymorphism and the phenotype of aspirin-intolerant chronic urticaria in a Korean population. J. Clin. Pharm. Ther. 2008, v. 33 (6), p. 691-697.
  14. Mastalerz L., Setkowicz M., Sanak M. et al. Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. Br. J. Dermatol. 2006, v. 154 (2), p. 256-260.
  15. Kim S.H., Ye YM., Lee S.K., Park H.S. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr. Opin. Allergy Clin. Immunol. 2006, v. 6 (4), p. 266-270.
  16. Pacor M.L., Di Lorenzo G., Mansueto P. et al. Relationship between human leucocyte antigen class I and class II and chronic idiopathic urticaria associated with aspirin and/or NSAIDs hypersensitivity. Mediators Inflamm. 2006, v. 5, p. 62489.
  17. Kim S.H., Kang Y.M., Kim S.H. et al. Histamine N-methyl-transferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria. Allergy. 2009, v. 64 (2), p. 213-221.
  18. Palikhe N.S., Kim S.H., Ye Y.M. et al. Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. Pharmacogenomics. 2009, v. 10 (3), p. 375-383.
  19. Grattan C.E. Autoimmune urticaria. Immunol. Allergy Clin. North. Am. 2004, v. 24 (2), p. 163-181.
  20. Brunetti L., Francavilla R., Miniello V. L. et al. High prevalence of autoimmune urticaria in children with chronic urticaria. J. Allergy Clin. Immunol. 2004, v. 114 (4), p. 922-927.
  21. Борзова Е.Ю. Клинико-патогенетические особенности аутоиммунной формы хронической крапивницы. Автореферат диссертации канд. мед. наук. М., 2004, 29 c.
  22. Sabroe R.A., Fiebiger E., Francis D.M. et al. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J. Allergy Clin. Immunol. 2002, v. 110 (3), p. 492-499.
  23. Tedeschi A., Asero R., Lorini M. et al. Different rates of autoreactivity in patients with recurrent idiopathic angioedema associated or not with wheals. J. Investig. Allergol. Clin. Immunol. 2012, v. 22 (2), p. 87-91.
  24. Kikuchi Y., Fann T., Kaplan A.P. Antithyroid antibodies in chronic urticaria and angioedema. J. Allergy Clin. Immunol. 2003, v. 112 (1), p. 218.
  25. Sabroe R.A., Francis D.M., Barr R.M. et al. Anti-Fc(episilon) RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J. Allergy Clin. Immunol. 1998, v. 102 (4 Pt 1), p. 651-658.
  26. Grattan C.E., O’Donnell B.F., Francis D.M. et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br. J. Dermatol. 2000, v. 143 (2), p. 365-372.
  27. Grattan C.E., Francis D.M., Slater N.G. et al. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet. 1992, v. 339 (8801), p. 1078-1080.
  28. Miescher S.M., Horn M.P., Pachlopnik J.M. et al. Natural anti-FcepsilonRIalpha autoantibodies isolated from healthy donors and chronic idiopathic urticaria patients reveal a restricted repertoire and autoreactivity on human basophils. Hum. Antibodies. 2001, v. 10 (3—4), p. 119-126.
  29. Stadler B.M., Pachlopnik J., Vogel M. et al. Conditional autoantibodies in urticaria patients: a unifying hypothesis. J. Investig. Dermatol. Symp. Proc. 2001, v. 6 (2), p. 150-152.
  30. Kern F., Lichtenstein L.M. Defective histamine release in chronic urticaria. J. Clin. Invest. 1976, v. 57 (5), p. 1369-1377.
  31. Luquin E., Kaplan A.P., Ferrer M. Increased responsiveness of basophils of patients with chronic urticaria to sera but hyporesponsiveness to other stimuli. Clin. Exp. Allergy. 2005, v. 35 (4), p. 456-460.
  32. Vonakis B.M., Vasagar K., Gibbons S.P. Jr et al. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2007, v. 119 (2), p. 441-448.
  33. Baker R., Vasagar K., Ohameje N. et al. Basophil histamine release activity and disease severity in chronic idiopathic urticaria. Ann. Allergy. Asthma. Immunol. 2008, v. 100 (3), v. 244-249.
  34. Eckman J.A., Hamilton R.G., Gober L.M. et al. Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J. Invest. Dermatol. 2008, v. 128 (8), p. 1956-1963.
  35. Grattan C.E., Dawn G., Gibbs S., Francis D.M. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin. Exp. Allergy. 2003, v. 33 (3), p. 337-341.
  36. Garmendia J.V., Zabaleta M., Aldrey O. et al. Immunophenotype characteristics of peripheral blood mononuclear leukocytes of chronic idiopathic urticaria patients. Invest. Clin. 2006, v. 47 (4), p. 361-369.
  37. Loria M.P., Dambra P.P., D’Oronzio L. et al. Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative. Immunopharmacol. Immunotoxicol. 2001, v. 23 (2), p. 205-213.
  38. Kessel A., Yaacoby-Bianu K., Vadasz Z. et al. Elevated serum B-cell activating factor in patients with chronic urticaria. Hum. Immunol. 2012, v. 73 (6), p. 620-622.
  39. Dos Santos J.C., Azor M.H., Nojima V.Y. et al. Increased circulating pro-inflammatory cytokines and imbalanced regulatory T-cell cytokines production in chronic idiopathic urticaria. Int Immunopharmacol. 2008, v. 8 (10), p. 1433-1440.
  40. Toubi E., Adir-Shani A., Kessel A. et al. Immune aberrations in B and T lymphocytes derived from chronic urticaria patients. J. Clin. Immunol. 2000, v. 20 (5), p. 371-378.
  41. Chen WC., Chiang B.L., Liu H.E. et al. Defective functions of circulating CD4+CD25+ and CD4+CD25- T-cells in patients with chronic ordinary urticaria. J. Dermatol. Sci. 2008, v. 51 (2), p. 121-130.
  42. Sun R.S., Sui J.F., Chen X.H. et al. Detection of CD4+ CD25+ FOXP3+ regulatory T-cells in peripheral blood of patients with chronic autoimmune urticaria. Australas. J. Dermatol. 2011, v. 52 (3), p. 15-18.
  43. Toppe E., Haas N., Henz B.M. Neutrophilic urticaria: clinical features, histological changes and possible mechanisms. Br. J. Dermatol. 1998, v. 138 (2), p. 248-253.
  44. Winkelmann R.K., Reizner G.T Diffuse dermal neutrophilia in urticaria. Hum. Pathol. 1988, v. 19, p. 389-393.
  45. Manoharan P., Fullen D., Avram A. Neutrophilic urticaria: whole-body (111)In-leukocyte scan and histological correlation. Eur. J. Nucl. Med. Mol. Imaging. 2006, v. 33 (12), p. 1523-1524.
  46. Criado R.F., Criado P.R., Martins J.E. et al. Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on histopathologic features. J. Dermatolog. Treat. 2008, v. 19 (2), p. 92-96.
  47. Lee K.H., Kim J.Y., Kang D.S., Choi Y.J., Lee W.J., Ro J.Y Increased expression of endothelial cell adhesion molecules due to mediator release from human foreskin mast cells stimulated by autoantibodies in chronic urticaria sera. J. Invest. Dermatol. 2002, v. 118 (4), p. 658-663.
  48. Bossi F., Frossi B., Radillo O. et al. Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy. 2011, v. 66 (12), p. 1538-1545.
  49. Caproni M., Volpi W., Giomi B. et al. Cellular adhesion molecules in chronic urticaria: modulation of serum levels occurs during levocetirizine treatment. Br. J. Dermatol. 2006, v. 155 (6), p. 1270-1274.
  50. Grattan C.E., D’Cruz D.P., Francis D.M. et al. Antiendothelial cell antibodies in chronic urticaria. Clin. Exp. Rheumatol. 1995, v. 13 (2), p. 272-273.
  51. Clough G.F., Church M.K. Histamine synthesis, action and inactivation: is the balance disturbed in allergy? Clin. Exp. Allergy. 1999, v. 29 (1), p. 9-11.
  52. Papadopoulou N., Kalogeromitros D., Staurianeas N.G. et al. Corticotropin-releasing hormone receptor-1 and histidine decarboxylase expression in chronic urticaria. J. Invest. Dermatol. 2005, v. 125 (5), v. 952-955.
  53. Lessof M.H., Gant V., Hinuma K. et al. Recurrent urticaria and reduced diamine oxidase activity. Clin. Exp. Allergy. 1990, v. 20 (4), p. 373-376.
  54. Kaplan A.P., Horakova Z., Katz S.I. Assessment oftissue fluid histamine levels in patients with urticaria. J. Allergy Clin. Immunol. 1978, v. 61 (6), p. 350-354.
  55. Guida B., De Martino C.D., De Martino S.D. et al. Histamine plasma levels and elimination diet in chronic idiopathic urticaria. Eur. J. Clin. Nutr. 2000, v. 54 (2), p. 155-158.
  56. Kanny G., Moneret-Vautrin D.A., Schohn H. et al. Abnormalities in histamine pharmacodynamics in chronic urticaria. Clin. Exp. Allergy. 1993, v. 23 (12), p. 1015-1020.
  57. Confino-Cohen R., Chodick G., Shalev V. et al. Chronic urticaria and autoimmunity: associations found in a large population study. J. Allergy Clin. Immunol. 2012, v. 129 (5), p. 1307-1313.
  58. Magen E., Mishal J., Zeldin Y. et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am. J. Med. Sci. 2010, v. 339 (6), p. 504-508.
  59. Magen E., Mishal J., Zeldin Y., Schlesinger M. Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. Allergy Asthma Proc. 2011, v. 32 (6), p. 460-466.
  60. Asero R., Tedeschi A., Coppola R. et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J. Allergy Clin. Immunol. 2007, v. 119 (3), p. 705-710.
  61. Cugno M., Marzano A.V., Tedeschi A. et al. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int. Arch. Allergy Immunol. 2009, v. 148 (2), p. 170-174.
  62. Takahagi S., Mihara S., Iwamoto K. et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy. 2010, v. 5 (5), p. 649-656.
  63. Kasperska-Zajac A. Acute-phase response in chronic urticaria. J. Eur. Acad. Dermatol. Venereol. 2012, v. 26 (6), p. 65-72.
  64. Tedeschi A., Asero R., Lorini M. et al. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin. Exp. Allergy. 2010, v. 40 (6), p. 875-881.
  65. Kasperska-Zajac A., Sztylc J., Machura E., Jop G. Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin. Exp. Allergy. 2011, v. 41.(10), p. 1386-1391.
  66. Ohtsuka T. Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria. Int. J. Dermatol. 2010, v. 49 (5), p. 579-584.
  67. Doeglas H.M., Klasen E.C., Bleumink E. Alpha 1-antitrypsin deficiency and PI typing in patients with chronic urticaria. Br. J. Dermatol. 1985, v. 112 (4), p. 381-385.
  68. Asero R. Sex differences in the pathogenesis of chronic urticaria. J. Allergy Clin. Immunol. 2003, v. 111 (2), p. 425-426.
  69. Kasperska-Zajac A., Brzoza Z., Rogala B. Lower serum dehydroepiandrosterone sulphate concentration in chronic idiopathic urticaria: a secondary transient phenomenon? Br. J. Dermatol. 2008, v. 159, p. 733-772.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2012



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies